Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy;

NCT06062030 | Completed Phase 3

• 1 other identifier: DWJ1609301
• Study Type: interventional
• Target: 215
• Locations: 1 country
• Sites: 1

Brief Summary

Phase of Development : III Sponsor : DAEWOONG PHARMACEUTICAL Study Sites and Principal Investigator : Dong ll Park M.D. Ph.D , Gastroenterology Kangbuk Samsung Hospital and other 6 study sites Study Period : From the protocol approval date (institutional review board, IRB) 24 Months Investigational product : Investigational Products DWJ1609 (sodium sulfate potassium sulfate, Magnesium Sulfate Anhydrous , simethicone, sodium picosulphate) Control Products DWC202304 (sodium sulfate potassium sulfate, Magnesium Sulfate Anhydrous , simethicone) Target Diseases : A person who needs treatment before colonoscopy (X-ray, endoscopy) Number of Subjects : 214 Subjects in total (85 subjects per group, 2 groups in total, considering a 20% dropout rate)

Conditions

Colonoscopy

Keywords

HCS; Bowel Cleansing

Outcome Measures

Primary Outcomes (1)

• The successful cleaning rate of the Harefield Cleansing Scale (HCS) phase rated as 'success'

  Evaluate the overall cleanliness in four steps according to the results of each of the five colon sections Grade A: 3 or 4 points for all colon sections Grade B: One or more sections with a score of 2 Grade C: One or more sections with a score of 1 Grade D: One or more sections with a score of 0 ※ If the overall colon cleanliness evaluation result is A grade, it is evaluated as successful 'failure (sealing success)' and C grade or D 'failure (sealing failure).

  from the beginning to the end of colonoscopy (Baseline)

Secondary Outcomes (12)

• Percentage of test subjects whose HCS cleanliness was evaluated as 'success'

  from the beginning to the end of colonoscopy(Baseline)

• Overall cleanliness ratio on HCS (overall cleansing rate)

  from the beginning to the end of colonoscopy(Baseline)

• Average score for each 5 compartments on the HCS (mean HCS score)

  from the beginning to the end of colonoscopy(Baseline)

• Percentage of test subjects with residual air bubbles on the bubble score

  from the beginning to the end of colonoscopy(Baseline)

• Percentage of test subjects found to have polyps or adenoma (detection of polyp or adenoma)

  from the beginning to the end of colonoscopy(Baseline)

Study Arms (2)

test group

EXPERIMENTAL

Investigational Products (DWJ1609) Number of tablets: 20 tablets in total Drinking water: 2,550 mL in total The day before the colonoscopy \[Day 1\] ▶ Common: Eat a light breakfast the day before the examination, or take only clear fluids. Take 10 tablets of DWJ1609 with 425 mL of water in the early evening (18:00-20:00) the day before the test, followed by 2 more doses of 425 mL of water for 1 hour (takes a total of 1,275 mL of water). On the day of colonoscopy \[Day 2\] ▶ Common: On the day of the examination, only clear liquids should be taken before the examination. Complete the clinical trial medication and additional water intake at least 2 hours prior to the test or at the time indicated by the tester In the evening before the test, take 10 additional DWJ1609 tablets with 425 mL of water in the morning (04:00\~08:00), 10 to 12 hours after taking DWJ1609, followed by 2 more doses of 425 mL of water for 1 hour (Total 1,275 mL of water).

Drug: DWJ1609

control group

ACTIVE COMPARATOR

Control Products (DWC202304) Number of tablets: 28 tablets in total Drinking water: 2,550 mL in total The day before the colonoscopy \[Day 1\] Take 14 tablets of DWC202304 with 425 mL of water in the early evening (18:00 to 20:00) the day before the test, followed by 2 more doses of 425 mL of water for 1 hour (takes a total of 1,275 mL of water). On the day of colonoscopy \[Day 2\] ▶ Common: On the day of the examination, only clear liquids should be taken before the examination. Complete the clinical trial medication and additional water intake at least 2 hours prior to the test or at the time indicated by the tester In the evening before the test, take 14 additional DWC202304 tablets with 425 mL of water in the morning of the test (04:00\~08:00), 10 to 12 hours after taking DWC202304, and then take 425 mL of water twice for 1 hour (total 1,275 mL of water).

Drug: DWC202304

Interventions

DWJ1609 DRUG

Drug of test group

test group

DWC202304 DRUG

Drug of control group

Also known as: Orafang Tab

control group

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult men and women 19 years of age or older as of the date of consent in writing
• a prospective colonoscopy patient
• kg/㎡ ≤ BMI \< 30 kg/㎡
• A person who voluntarily agrees to participate in this clinical trial and signs a written agreement Abbreviation: BMI = body mass index

You may not qualify if:

• A person who undergoes colonoscopy for the following therapeutic purposes (1) balloon dilatation of the stenosis area (2) non-toxic giant colon or decompression of the S-phase colitis (sigmoid volvulus) (3) Removal of foreign substances (4) Vascular dysplasia, ulcer, tumor and treatment of bleeding after polypectomy (5) Treatment for stenosis or tumor bleeding (palliative treatment)
• A person whose past history has been confirmed during a screening visit (1) Severe heart disease (insecurity angina, acute myocardial infarction, acute heart failure, cardiomyopathy, etc.) or acute respiratory failure within 24 weeks prior to screening (2) Epilepsy or seizures within 96 weeks prior to screening (3) Clinically significant intestinal surgical history regardless of duration (e.g., colon premature surgery, colon resection, etc.)
• a. However, appendectomy and hemorrhoids are excluded
• A person who has been identified or suspected of the following comorbidities during a screening visit (1) active intestinal hemorrhage (2) gastrointestinal obstruction (intestinal obstruction, gastrointestinal obstruction, etc.), gastrointestinal perforation, gastric discharge disorder (gastrointestinal paralysis, gastric congestion, etc.) (3) Inflammatory bowel disease (ulcerative colitis, Crohn's disease, toxic colitis, toxic colitis, etc.) (4) Gastrointestinal ulcers, colorectal mucosal ulcers, ischemic colitis (5) an acute abdominal condition requiring surgery (6) A person who has been identified with the following major cardiovascular diseases
• ① congestive heart failure
• ② NYHA functional classification III or IV
• ③ Clinically significant arrhythmia identified by ECG, QTcFb delay (Male \> 450 msec, Female \> 470 msec) etc.
• b. QTc interval corrected by Fridericia's formula (7) Despite adequate medication, uncontrolled hypertension (SBP \> 170 mmHg and DBP \> 100 mmHg) (8) Diabetes undergoing insulin treatment or in need of insulin treatment (9) Clinically significant electrolyte abnormalities (sodium, potassium, calcium, magnesium, chloride, bicarbonate, phosphate etc.) (10) Those who are at risk of dehydration (transverse fusion, ascites, etc.) (11) Severe renal impairment (eGFRc \< 30 mL/min/1.73m2) c. MDRD-eGFR (mL/min/1.73m2) = 186 × (serum creatinine concentration)-1.154 × (age)-0.203 (× 0.742, Female) (12) Child-Pugh class B or C (13) ALT or AST \> three times the normal upper limit of the trachea (14) Severe nausea or vomiting that makes it difficult to participate in clinical trials (15) Active infection or high fever above 38℃ (except acute upper respiratory tract infection or local skin infection) (16) Active hepatitis B or C d. Defined as HBsAg positive during screening e. Defined as HCV Ab positive during screening (17) Test results of HIV antibodies and antibody test results
• A person who is administering the following drugs during a screening visit or is expected to be administered by the time of completion of a colonoscopy (Day 2; Visit 2) (1) Constipation patients who are regularly administered laxatives or gastrointestinal motility promoters within 12 weeks prior to screening (e.g., two to three times a week or more) (2) Administration of laxatives, enema, simethicone, 5HT4 receptor agonist, iron preparation, opioid excluding clinical trial drugs within 7 days of clinical trial drug administration (Day 1)
• A person who is hypersensitive to the ingredients of a clinical trial drug
• a pregnant woman or a lactating woman
• Fertility women and men who have a pregnancy plan or do not agree to perform appropriate contraception during the clinical trial. Appropriate contraception in this trial is as follows
• hormonal contraceptive
• implantation of intrauterine device or intrauterine system
• Infertility procedures/surgery (e.g., bilateral ovarian ligation, vasectomy)

Sponsors & Collaborators

• Daewoong Pharmaceutical Co. LTD.: lead

Study Sites (1)

Kangbuk Samsung Hospital

Seoul, Korea, South Korea

Location

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: CARE PROVIDER
• Masking Details: Single-blinded (Investigator),
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 29, 2023
• First Posted: October 2, 2023
• Study Start: March 8, 2024
• Primary Completion: June 3, 2024
• Study Completion: June 28, 2024
• Last Updated: December 20, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)